摘要
目的:观察以疏利少阳为治疗原则的肾络宁对IgA肾病肾小球硬化模型的影响。方法:SD大鼠90只随机分为正常组、模型组、苯那普利组、肾炎康复片组、肾络宁组。采用单肾切除后反复尾静脉注射较大剂量葡萄球菌肠毒素B(SEB)的方法,制作接近人类IgA肾病肾小球硬化病变发展过程的大鼠实验动物模型,并观察不同时间节点时,各组转化生长因子-β1(TGF-β1)、纤维连结蛋白(FN)的表达情况。结果:模型组肾小球TGF-β1、FN表达量升高,各治疗组肾小球中TGF-β1、FN表达量下降。与苯那普利、肾炎康复片组比较,肾络宁组在第9周后的治疗效果更为突出。结论:以疏利少阳为治疗原则的肾络宁对防治IgA肾病肾小球硬化有良好的疗效。
Objective：To observe the efficacy of ＂Shenluoning Compound＂ on glomerularsclerosis of lgA nephropathy. Methotis： Ninety SD rats were randomly divided into five groups： normal group,model group, benazepril group, ＂Shenyan Kangfu Tablet＂ group, ＂Shenluoning Compound＂ group. IgA nephropathy glomerularsclerosis rat model was established by intravenous injection of a large dosage of staphyloentero-toxin B repeatedly after unilateral nephrectomy. The expressions of transforming growth factor β1 （TGF-β1） and fibronectin （FN）at different times were detected. Results：The levels of TGF-β1 and FN increased in model group, but decreased in the other three treatment groups. Compared with those of benazepril group and ＂Shenyan Kangfu Tablet＂ group, the therapeutic efficacy of ＂Shenluoning Compound＂ group was significantly better after nine-week treatment. Conclusion： ＂Shenlu- oning Compound＂ is effective on glomerularsclerosis of IgA nephropathy.
出处
《上海中医药大学学报》
CAS
2007年第3期63-65,共3页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(30472129)
